Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications drug pricing reform efforts blueprint turns 1 year old
… Medicare Drug Price Negotiation (DPN): Implications for Industry Share … guidance is currently written, negotiations will last for 1 year and prices will become effective 2 years after that. The …
… Medicare Drug Price Negotiation Under the Inflation Reduction Act … Medicare to directly negotiate - for the first time - pricing for certain drugs. The Maximum Fair Price (MFP) … were selected solely based on total Medicare spend. Round 1 price negotiations will be completed in 2024, and the …
… the first 10 chosen drugs, which will take effect in 2026, Reform of the EU Pharmaceutical Legislation and Joint … Germany, the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) in the UK, and ongoing drug pricing reforms in Japan, to name but a few. This …
… your success, how do you not? We can help you navigate the pricing and reimbursement bodies that ultimately determine … in accordance with Section 114 of the 1997 Food and Drug Administration Modernization Act Summaries of relevant … patient populations, and results from your modeling efforts are consistent with payer and payer advisor …
… Medicare Drug Price Negotiation: Opportunities for Manufacturers in … on 2 July 2024. The form includes information on drug pricing, costs of development, status of relevant patents, … in the second negotiation cycle (IPAY 2027). See Table 1 at the end of this article for a quick reference guide to …
… bring more equity to health technology assessments (HTAs), drug and medical device developers are looking to understand … to address potential challenges they may face in drug development as they move toward regulatory approval and … development, regulatory processes, market access, and pricing. Integrated evidence planning and evidence generation …
… Mounting Evidence Suggests Century-Old Hypothesis on How Major Arteries Function is Incorrect …
… Multi-Criteria Decision Analysis Most drug development and commercialization choices are complex. … Market Access and Post-Approval Decisions From making drug development decisions, to phase III evidence plans, to developing pricing strategies and value messages, MCDA can be used to …
… key clinical and economic evidence to support your pricing, reimbursement, and formulary inclusion efforts. In addition to being used in response to unsolicited …
… trials Implement comparative effectiveness research Make pricing decisions Achieve formulary acceptance Gain … budget and population health impact, and value-based pricing Comparative Effectiveness Indirect and mixed …